A5087907466- Inflammatory Bowel Disease
- Microscopic Colitis
- Clostridium difficile and Clostridium perfringens research
- Gut microbiota and health
- Eosinophilic Esophagitis
- Gastrointestinal motility and disorders
- Pharmacological Effects of Natural Compounds
- Liver Diseases and Immunity
- Pregnancy and Medication Impact
- Diagnosis and treatment of tuberculosis
- Nosocomial Infections in ICU
- Immunodeficiency and Autoimmune Disorders
- Health Systems, Economic Evaluations, Quality of Life
- Celiac Disease Research and Management
- Helicobacter pylori-related gastroenterology studies
- Biosimilars and Bioanalytical Methods
- Gastrointestinal Tumor Research and Treatment
- Probiotics and Fermented Foods
- Botulinum Toxin and Related Neurological Disorders
- Diet and metabolism studies
- Viral gastroenteritis research and epidemiology
- Chronic Lymphocytic Leukemia Research
- Tuberculosis Research and Epidemiology
- Pharmaceutical studies and practices
- Colorectal Cancer Treatments and Studies
Brigham and Women's Hospital
2016-2025
Harvard University
2016-2025
Crohn's and Colitis UK
2024
Woman's Hospital
2021-2022
Women's Hospital
2017
Association for Language Learning
2017
Objective Faecal microbiota transplant (FMT) effectively treats recurrent Clostridioides difficile infection (rCDI), but its mechanisms of action remain poorly defined. Certain bile acids affect C. germination or vegetative growth. We hypothesised that loss gut microbiota-derived salt hydrolases (BSHs) predisposes to CDI by perturbing metabolism, and BSH restitution is a key mediator FMT’s efficacy in treating the condition. Design Using stool collected from patients donors pre-FMT/post-FMT...
Summary Background The healthy microbiome protects against the development of Clostridium difficile infection ( CDI ), which typically develops following antibiotics. metabolises primary to secondary bile acids, a process if disrupted by antibiotics, may be critical for initiation . Aim To assess levels and acids associated with microbial changes. Methods Stool serum were collected from patients (i) first fCDI (ii) recurrent rCDI ) (iii) controls. 16S rRNA sequencing salt metabolomics...
The prevalence and perceived effectiveness of marijuana use has not been well studied in inflammatory bowel disease (IBD) despite increasing legal permission for its Crohn's disease. Health care providers have little guidance about the IBD symptoms that may improve with use. aim this study was to assess prevalence, sociodemographic characteristics, benefits among patients IBD.Prospective cohort survey patterns at an academic medical center.A total 292 completed (response rate = 94%); 12.3%...
Fecal microbiota transplantation (FMT) is a promising therapeutic modality for the treatment and prevention of metabolic disease. We previously conducted double-blind, randomized, placebo-controlled pilot trial FMT in obese metabolically healthy patients which we found that enhanced gut bacterial bile acid metabolism delayed development impaired glucose tolerance relative to placebo control group. Therefore, secondary analysis fecal samples collected from these assess potential microbial...
Abstract Background Oral ritlecitinib (RIT; JAK3/TEC family kinase inhibitor) and brepocitinib (BRE; TYK2/JAK1 are being assessed in a 64-week (wk) phase 2a randomised, double-blind, induction-maintenance, umbrella study (PIZZICATO; NCT02958865) participants (pts) with moderate-to-severe active Crohn’s disease (CD) inadequate, loss of response or intolerance corticosteroids, immunosuppressants biologics. We report the efficacy safety results from 12-wk induction period. Methods Pts 18-75...
Abstract Background Ulcerative colitis (UC) symptoms are associated with impaired health-related quality of life (HRQoL). The Phase 3 QUASAR maintenance study (NCT04033445) evaluated the efficacy and safety guselkumab (GUS) in participants (pts) moderately to severely active UC who demonstrated a clinical response GUS intravenous (IV) induction. is selective dual-acting IL-23p19 subunit inhibitor that potently blocks IL-23 binds CD64, receptor on cells produce IL-23. Here we report effect...
Abstract Background Guselkumab (GUS), a dual-acting IL-23 inhibitor that potently neutralizes and binds to CD64 (a receptor on cells produce IL-23), is currently approved in the United States for treatment of ulcerative colitis (UC) worldwide plaque psoriasis psoriatic arthritis. While GUS has been shown be safe Crohn’s disease (CD) UC, safety results have only reported individual trials date. To characterize overall profile inflammatory bowel (IBD), we evaluated pooled data from Phase 2/3...
Abstract Background Tumor necrosis factor-like ligand 1A (TL1A) is upregulated in inflammatory bowel disease and believed to promote inflammation intestinal fibrosis. RO7790121, an anti-TL1A antibody, showed promising results the phase IIa TUSCANY trial.1 Here we report post-hoc analyses of patient-reported outcomes from TUSCANY-2 trial. Methods This IIb, multicenter, randomized, double-blind, treat-through, dose-ranging study evaluated RO7790121 patients (pts) aged 18–75 years with...
Abstract Background Risankizumab (RZB) is a high-affinity humanized IgG1 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine, thereby inhibiting its interaction with receptor.1 RZB was intentionally designed modifications could contribute prolonged half-life, low immunogenicity, and increased stability bioavailability.1 The objective this post-hoc analysis characterise pharmacokinetic (PK) pharmacodynamic (PD) effects following withdrawal in patients...
Abstract Background Tumor necrosis factor-like ligand 1A (TL1A) is upregulated in inflammatory bowel disease, promoting inflammation and intestinal fibrosis. Targeting TL1A with the anti-TL1A antibody RO7790121 showed significant endoscopic improvement favorable safety phase IIa TUSCANY trial1 subsequent IIb TUSCANY-2 trial (NCT04090411) patients (pts) moderately to severely active ulcerative colitis (UC). Here we report histologic remission data from TUSCANY-2. Methods Pts aged 18–75 years...
Abstract Background Guselkumab (GUS) is a selective dual-acting IL-23p19 subunit inhibitor that potently blocks IL-23 and binds to CD64, receptor on cells produce IL-23. GUS demonstrated efficacy in patients (pts) with ulcerative colitis (UC) who received intravenous (IV) induction subcutaneous (SC) maintenance (QUASAR). We evaluated the safety of SC ASTRO, phase 3, randomised, double-blind, placebo (PBO)-controlled, parallel-group, multicenter trial pts moderately severely active UC....
Fecal microbiota transplantation (FMT) is a highly effective therapy for recurrent Clostridioides difficile infection. Stool donors are essential, but difficult to recruit and retain. We aimed identify factors influencing willingness donate stool. This multi-center study with 32-item questionnaire targeted young adults health care workers via social media university email lists in Edmonton Kingston, Canada; London Nottingham, England; Indianapolis Boston, USA. Items included baseline...
Abstract Background The QUASAR Induction Study 1 (NCT04033445) is a phase 2b randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of guselkumab (GUS), an interleukin-23 p19 subunit antagonist, as induction therapy in patients with moderately severely active ulcerative colitis (UC) who had inadequate response or intolerance conventional (ie, thiopurines corticosteroids) advanced tumor necrosis factor alpha antagonists, vedolizumab, tofacitinib)....
Abstract Background Fatigue is a common symptom in patients with ulcerative colitis (UC) that impairs health-related quality of life. The Phase 3 QUASAR Induction Study (NCT04033445) was randomized, double-blind, placebo-controlled, parallel-group, multicenter study guselkumab (GUS), an interleukin-23 p19 subunit antagonist, moderately to severely active UC. impact GUS IV induction on patient-reported symptoms fatigue reported here. Methods Patients were randomized 3:2 receive 200 mg or...
Abstract Background Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. We evaluated tofacitinib efficacy and safety in 52-week maintenance study, OCTAVE Sustain, by baseline Mayo endoscopic subscore (MES) following 8-week induction. Methods The proportion patients achieving endpoints at Week 24 or 52 Sustain was MES Using logistic regression, difference effect (tofacitinib vs. placebo) between (0 1) each endpoint assessed. Adverse events...
Abstract Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of UC. We aimed to describe real-world experience and corticosteroid utilisation patients treated with tofacitinib in a US claims database. Methods Patients UC diagnosis who initiated tofacitinib, vedolizumab or tumour necrosis factor (TNFi) between May 2018 July 2019 were identified from Optum Research Database. Demographic clinical characteristics TNFi described. Oral use prior following initiation...